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POB2 RECENT TRENDS AND A FUTURE FORECAST OF POPULATION BODY MASS INDEX LEVELS IN THE UNITED KINGDOM
Woehl A 1 , Currie CJ 2 1 Kiel University, Kiel, Germany; 2 Cardiff University, Cardiff, UK OBJECTIVE: Patterns of obesity are an important public health consideration. The purpose of this study was to determine the past and future population trends of obesity in the UK (UK). METHODS: Data describing body mass index (BMI) were abstracted from the English Health Survey's from 1991 to 2002, inclusive. The UK was assumed to follow the same pattern of change in body composition as England. The distributional pattern of BMI was determined and age and sex specific changes in the distribution described over the period. Data were standardized to the UK population in 2001. Ethnicity was accounted for in the forecast using general linear models for age and sex specific groups applied to government forecasts of future demography. RESULTS: BMI increased by a mean value of 
POB3 PREVALENCE TRENDS OF OVERWEIGHT AND OBESITY AND TREATMENT PATTERNS FOR WEIGHT CONTROL IN THE US POPULATION
Vo L,Valiyeva E, Shin HC, Suh DC, Barone JA Rutgers University, Piscataway, NJ, USA OBJECTIVES: To assess epidemiologic trends of overweight and obesity and to examine treatment patterns to control weight in children/adolescents aged 2-19 years and for adults ≥20 years old. METHODS: The Third National Health and Nutrition Examination Survey (NHANES III) conducted in 1988 -1994 and NHANES 2001 -2002 were used. Children/adolescents were classified as at risk for overweight if body mass index (BMI) was ≥85th-<95th percentile and as overweight if BMI was at ≥95th percentile of the sex-specific BMI for age growth charts. Adults were categorized as overweight or obese (BMI ≥ 30.0). Duration of physical activity was calculated using leisure-time physical activity to assess compliance of CDC/ASCM recommendations. SAS and SUDAAN software were employed to account for the complex survey design. RESULTS: The proportions of children/adolescents at risk for overweight or overweight increased from 13.1% to 14.5% and from 11.1% to 15.5%, respectively, between 1988-1994 and 2001-2002 . The prevalence of overweight and obesity for adults also increased from 32.8% to 35.2% and from 22.3% to 30.2%. Prevalence of diabetes in overweight and obese adults slightly increased between 1988-1994 (5.5%, 10.0% respectively) and 2001-2002 (6.1%, 10 .6%). However, LDL ≥ 130 mg/dL was less prevalent in 2001-2002 (53.4% to 41 .8% for overweight and 54.0% to 41.0% for obesity). Overall, 10.3% of overweight and 14.9% of obese adults used liquid diet formula, prescription drugs, non-prescription drugs, laxatives or vomiting to control weight in [2001] [2002] . Only 1% of overweight and 3% of obese adults took prescribed diet pills. About 47% of overweight and 43% of obese adults either took medications or complied with physical activity recommended by CDC/ASCM to control weight. CONCLUSIONS: Overweight and obesity have become more prevalent in the US population during the past decade. However, very few patients took medications prescribed by their physicians to lose or control their weight. Kiel University, Kiel, Germany; 2 Cardiff University, Cardiff, UK; 3 University Hospital of Wales, Cardiff, UK BMI is widely used to measure obesity in outcome studies, but other easily collected measures are available to characterise bodily shape. OBJECTIVE: The objective of this study was to determine whether BMI and waist-to-hip ratio (W : H-R), as standard measures of obesity, collectively better explained the likelihood of obesity-related complications. METHODS: This retrospective study used data from the England Health Survey, a national representative survey of the general population. Data describing BMI, obesity related diseases and other anthropometric measurements were abstracted from the survey 1991 to 1994, and 1997 to 2002. Using this data, a model was developed to account for various factors that could effect the development of obesity related diseases: diabetes, stroke, heart attack, hypertension and other vascular diseases. Using logistic regression, the association of between BMI categories further broken down by W : H-R categories was determined. The results were standardized for age, sex and ethnicity to generate standardized odds ratios comparing the accuracy of different anthropometric measurements and its combinations to predict obesity related diseases. RESULTS: BMI and W : H-R were independent predictors of disease in obesity. Using both these measures a more precise prediction of the likelihood of developing obesity related complications. Odds ratios in the group with the highest BMI of the sample varied between 1.6 and 2.8 conditional on their W : H-R. Patients with a medium BMI but high W : H-R had a higher relative risk (odds ratio 1.8) than patients with a high BMI but low W : H-R (odds ratio 1.6). These patterns were even more obvious in diabetic patients. Similar results could be shown by combining BMI and waist circumference only. CONCLUSIONS: BMI in addition to W : H-R or waist circumference is a better and more precise predictor of obesity-related complications, and should where possible be preferentially used. Longitudinal obesity-related outcome data are needed. 3 Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, USA; 4 Kaiser Permanente, Aurora, CO, USA OBJECTIVE: To examine the cost-effectiveness of sibutramine plus a structured weight management program (WMP) versus only structured WMP. METHODS: Cost-effectiveness analysis based on a randomized controlled trial conducted within a managed care organization. The target population was obese or overweight persons. The economic time horizon was two years (pre and post study enrollment). Perspective was from that of a managed care organization. The treatment arms consisted of either sibutramine plus structured WMP or only WMP. The primary outcomes were change in weight and percent change in weight over 12 months, and change in obesity-related and total medical costs 12 months prior to and 12 months after enrollment. Non-parametric bootstrap was used to generate 95% confidence intervals for incremental cost-effectiveness ratios. RESULTS: A total of 501 subjects were enrolled in the study, 281 receiving sibutramine plus structured WMP and 220 receiving only structured WMP. The mean (SD) weight loss was significantly greater in the sibutramine (13.7 (15.5) lbs) group than the non-drug group (5.0 (13.2) lbs) (p < 0.001). Obesity-related total cost between groups were different (p < 0.001), with a median of $408 for sibutramine compared to $58 for the nondrug group. The ICER for sibutramine was $44 (95% CI: $42 to $46) per additional pound of weight loss. Sensitivity analysis suggested that changes in physician costs a negligible effect on the results. If the cost of sibutramine was excluded, there was no difference between the groups with respect to obesity-related costs. A limitation of this study is that costs were estimated using national fees schedules for hospital and physician visits and average wholesale price for medications. CONCLUSION: Patients enrolled in a weight management program receiving sibutramine had greater weight loss and decrease in BMI at greater cost than did patients enrolled in the same program who did not receive sibutramine.
POB4 RELIABLE MEASUREMENT OF OBESITY: RISK OF VASCULAR DISEASE COMPLICATIONS AS A FUNCTION OF BODY MASS INDEX AND WAIST-TO-HIP RATIO

Woehl
POB5 COST EFFECTIVENESS OF SIBUTRAMINE IN THE LONG-TERM OUTCOMES OF SIBUTRAMINE EFFECTIVENESS ON
POB6 COSTS OF OBESITY IN THE UNITED STATES AND EUROPE: A REVIEW OF THE LITERATURE
Budhiarso I, Derleth A, Martin ML Health Research Associates, Mountlake Terrace, WA, USA OBJECTIVE: To provide a broad picture of the costs of obesity using data from the US and major European countries. METHOD: Literature (2000 Literature ( -2004 was searched via Medline using cost keywords: cost, cost-effectiveness, cost-benefit, costefficiency. Selected citations were reviewed by title and abstract, followed by retrieval of relevant articles, review and synthesis of cost information. RESULT: Direct medical expenditures for obesity in the US were estimated to be between $70-$94 billion and $331 billion-with all obesity associated comorbidities included. This represented approximately 5.7%-9.4% of the adult direct health spending. Cardiovascular disease and diabetes constituted approximately 70% of the obesity-related cost. Indirect costs associated with obesity were estimated to be at least $48 billion. The expected mean costs for persons with BMI = 30-34 and BMI = 35-39 were 12% and 19% higher (respectively) than persons with BMI < 25. Women spent more than men for obesity care. In the US, Wyoming showed the lowest expenditure for obesity ($87 million), and California the highest ($7.7 billion). Direct costs of obesity in Europe were estimated between 1.5% and 4% of total health expenditures, with the UK, Germany and France all showing similar expenditures (1.5%). Expenses associated with comorbid hypertension, coronary heart disease and diabetes were the main drivers of cost in the UK (80.5%). Indirect costs in the UK were estimated at £2.1 billion, of which £1.3 billion (61%) was due to work loss. Drug interventions using Orlistat, Sibutramine and Metformin were all cost-effective with the cost per QALY gained ranging between $8,327 to $19,968 (£4,780 to £45,881) . CONCLUSION: The costs attributable to obesity in both the US and Europe represented a significant portion of the national health expenditure for those countries reviewed, with comorbid cardiovascular disease and diabetes constituting the major components of obsesity associated health care costs. ) was chosen and it was assumed that no medical intervention was undertaken. The perspective was third-party reimbursement in a US setting. Mortality was adjusted for age, gender, race and BMI by Cox regression and applied to US life tables. Costs and utility values were adjusted for age, gender and BMI. US costs were derived from published resources and inflated to year 2004 figures. Reported outcomes included direct medical costs, life expectancy (LE) and quality-adjusted life expectancy (QALE) all of which were discounted at 3% according to US guidelines. RESULTS: Mean lifetime costs were $85,393 (±1545), $97,156 (±1836) . CONCLU-SIONS: Raised BMI is associated with substantially greater direct medical costs and diminished LE and QALE. This model will allow health economic evaluations of the outcomes of various anti-obesity interventions.
POB7 LIFETIME COSTS ASSOCIATED WITH OBESITY: A COMPUTER SIMULATION MODEL
